Galderma to Present 19 Abstracts at EADV 2026, Highlighting…

Event summary

Galderma will present 19 abstracts at the 2026 European Academy of Dermatology and Venereology (EADV) Congress, showcasing advancements in skin diseases, skin longevity, and real-world patient experiences.
Key presentations include long-term safety and efficacy data for Nemluvio in atopic dermatitis and prurigo nodularis, with findings from the ARCADIA open-label extension study spanning 152 weeks.
Galderma will host a symposium on October 2, 2026, exploring the burden of itch in atopic dermatitis and prurigo nodularis, and the role of neuroimmune cytokines in improving patient outcomes.
New research on Cetaphil will focus on sensitive skin health, skin longevity, and innovative technologies, including a gentle cleanser and barrier-restoring moisturizer regimen for atopic dermatitis.
Additional presentations will cover acne management innovations, including the anti-inflammatory activity of a lysine-based dendritic polymer and niacinamide, and the effects of Aklief on skin redness and color evenness.

The big picture

Galderma's extensive presence at EADV 2026 underscores its commitment to advancing dermatology through scientific innovation. The company's focus on long-term outcomes in chronic skin diseases and emerging fields like skin longevity aligns with broader industry trends towards personalized and preventive skincare solutions. With a portfolio spanning Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology, Galderma is well-positioned to capitalize on the growing demand for evidence-based care and targeted treatments.

What we're watching

Pipeline Advancement: How Galderma's new data on long-term outcomes in chronic inflammatory skin diseases will position its pipeline for future growth and competitive differentiation.
Skin Longevity: Whether Galderma's focus on skin longevity will unlock new market opportunities and drive innovation in dermatological skincare.
Regulatory Approvals: The pace at which Galderma can translate its research findings into regulatory approvals and commercial products, particularly in emerging fields like skin longevity.